查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827431

气喘药物市场（按产品类型、药物类别、交付方式、分销管道和最终用户划分）—2025-2032 年全球预测

Asthma Drugs Market by Product Type, Drug Class, Delivery Mode, Distribution Channel, End Users - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年气喘药物市场将成长至 396.2 亿美元，复合年增长率为 6.29%。

主要市场统计数据
基准年2024年 243亿美元
预计2025年 257.5亿美元
预测年份：2032年 396.2亿美元
复合年增长率（%） 6.29%

对当前治疗环境、设备创新、监管压力和相关人员期望的权威定位，定义气喘药物策略

气喘仍然是一种慢性呼吸系统疾病，其临床和营运挑战持续推动製药和医疗设备领域的创新。虽然治疗模式历来着重于缓解症状和预防病情恶化，但向精准医疗、改进的设备工程和整合护理模式的稳步转变正在重塑临床路径和采购重点。在此背景下，从製造商到医疗保健提供者和付款人的相关人员正在重新评估产品系列、患者支援服务和分销策略，以应对不断变化的患者期​​望、监管要求和技术能力。

当代情势反映了临床科学与系统思维的交会。吸入器设计和连接技术的进步使得依从性监测和远端系统管理成为可能，而不断发展的临床指导则鼓励早期疗育和分层治疗选择。同时，供应链考量、製造专业化和成本控制压力促使人们重新评估采购和生产布局。总而言之，这些动态变化为那些能够在临床可靠性、营运敏捷性和数据主导决策之间取得平衡的组织带来了颠覆和机会。

设备与数位融合、个人化治疗途径、不断变化的报销优先顺序以及供应链弹性如何重塑气喘药物的竞争优势

气喘药物领域正在经历一场变革，其驱动力在于多种力量的汇聚，这些力量正在重新定义竞争优势和病患治疗效果。首先，设备创新正在超越简单的给药机制，转向整合的数位生态系统，将吸入器或雾化器与感测器、行动应用程式和云端分析相结合。这一趋势正在将价值提案从单纯的产品交付转向疗效和参与度，透过加强药物依从性追踪，并在门诊期间实现由医疗服务提供主导的干预。

其次，随着临床医生和付款方在中重度疾病的治疗中优先考虑表型和生物标记驱动的方法，临床个人化治疗正蓬勃发展。因此，治疗途径变得更加细緻，针对不同发炎特征的患者，更倾向于采用标靶药物和合併用药策略。第三，监管和报销格局正在演变，以奖励现实世界的疗效和成本控制，这增加了强有力的上市后证据产生和付款方参与的重要性。此外，在全球经济动盪之后，供应链的韧性和采购敏捷性变得越来越重要，迫使製造商重新评估其采购、库存策略和本地製造方案。

最后，患者期望和医疗服务模式也在同步变化。远端医疗的普及、护理分散化以及居家监测正在扩大气喘管理的接触点，因此需要能够简化使用并提高依从性的整合解决方案。总的来说，这些转型有利于那些能够将设备创新、临床证据、供应链适应性以及与相关人员一致的价值命题整合到连贯的商业策略中的组织。

分析回顾 2025 年美国关税如何影响气喘药物的采购成本、製造足迹和筹资策略

美国决定于2025年征收新关税，对气喘药物供应链、商业策略和长期投资选择产生了多方面的影响。对某些原材料、成品和零件征收的进口关税增加了某些依赖全球采购的製造商的到岸成本。因此，采购团队和合约製造商加快了重新评估供应商协议、寻找近岸和国内替代方案以及协商长期供应协议的步伐，以降低成本波动。

因此，拥有垂直整合製造和多元化供应商基础的製造商的稳定性有所提升，而那些集中于受影响进口类别的製造商则面临营运压力。为此，一些公司调整了资本投资的优先级，转向本地设备生产线和组装业务，同时在监管和品质合规成本与经济效益之间取得平衡。此外，关税主导的成本压力影响了与经销商和付款人的定价谈判，导致相关人员强调附加价值服务，例如依从性计划和病患支持，以保持其商业性地位。

从策略角度来看，关税环境提升了采购和产品设计敏捷性的重要性。那些主动重新设计零件以使用替代材料和模组化架构的公司，其韧性更强。此外，重新分类零件、利用自由贸易协定以及增加库存缓衝等过渡措施，也帮助一些公司吸收了短期衝击。展望未来，这些政策变化的累积影响正促使人们重新思考供应链布局策略、製造投资，以及在成本优化与依赖吸入器、雾化器和口服疗法的患者持续护理之间的平衡。

综合細項分析揭示了产品类型、药品类别、交付方式、分销管道和最终用户人口统计数据如何影响临床采用和商业策略

透过分析产品类型、药品类别、给药方式、分销管道和最终用户，可以揭示商业性和临床动态。依产品类型划分，吸入器、雾化器和片剂到片剂製剂各自展现出不同的采用驱动因素。吸入器和雾化器优先考虑设备人体工学、剂量准确性和促进依从性，而口服製剂则强调系统性耐受性和针对特定患者群体的便利性。因此，产品开发团队必须将研发投资与设备可用性和病患偏好资料结合，以最大限度地提高临床应用率。

依药物类别检视市场格局，突显出独特的治疗和监管考量。沙丁胺醇和β受体促效剂主要用于急性症状缓解和即时扩张支气管，而支气管扩张剂和皮质类固醇则构成需要长期依从性和安全性监测的维持治疗方案的支柱。白三烯调节剂为某些发炎表型提供了替代或辅助治疗途径，并可作为偏好或需要非吸入疗法患者的口服选择。因此，处方定位和临床讯息必须区分急性救援治疗和维持治疗，同时考虑安全性和给药途径特异性的益处。

给药方式大致分为吸入和口服，会影响临床疗效和病人接受度。吸入疗法可将药物靶向输送至肺部，并可快速启动给药，但对患者的操作技能要求更高，并且可能需要高级培训和后续随访。口服疗法方便且易于患者熟悉，但可能存在不同的全身暴露和依从性挑战。因此，商业化策略应加强对口服疗法依从性的支持，同时整合病患教育倡议和吸入产品设备培训计画。

医院药局、线上药局和零售药局各自应对不同的采购行为和物流限制。医院药局通常在机构采购框架内处理急重症病例；线上药局提供便利的订阅模式，支持慢性病护理的连续性；而零售药局在即时咨询和即时取得方面仍然发挥着重要作用。因此，根据预测的处方模式和支付管道调整分销策略，对于确保产品供应和患者依从性至关重要。

最后，将终端使用者细分为门诊手术中心、家庭护理机构以及医院和诊所，凸显了其多样化的使用和支援需求。门诊手术中心优先使用短效药物进行术前和术后管理；居家照护机构需要耐用、易用且具有远端监控功能的设备；医院和诊所则需要可靠的供应和全面的临床支援材料。整合这些细分层级，有助于制定细緻的商业性策略，在产品设计、证据生成和服务交付之间取得平衡，以满足临床医生、看护者和患者的期望。

美洲、中东和非洲以及亚太地区对监管复杂性、付款人期望和商业性执行的不同区域观点

美洲、欧洲、中东和非洲以及亚太地区的动态正在影响监管途径、报销框架和商业性重点，为气喘药物相关人员创造了独特的机会和限制。在美洲，付款方审查和采购的加强促使人们关注现实世界的疗效、成本效益证据以及能够显着减少病情加重和住院的服务模式。在该地区运营的製造商优先考虑全面的卫生经济学文献和综合的患者支持，以满足处方决策者和大型综合交付网络的需求。

欧洲、中东和非洲地区管理体制和报销环境的差异性要求打入市场策略具有适应性。在一些欧洲国家，集中采购和基于价值的合约模式日益重要；而在中东和非洲部分地区，市场准入的挑战和基础设施的多样性有利于建立稳固的经销伙伴和开展能力建设项目。因此，跨境策略必须在集中式证据产生与本地客製化的付款人参与和供应链解决方案之间取得平衡。

亚太地区既具有快速应用的潜力，也面临医疗保健体系、监管标准和病患群体多样性的复杂性。该地区许多司法管辖区正在迅速采用数位医疗技术，为连网吸入器解决方案和远端监控整合提供了肥沃的土壤。同时，製造商必须兼顾价格敏感度和当地製造业的预期，通常需要创造性的商业化模式、技术转移和策略伙伴关係关係，以支持永续的可及性和规模化。在所有地区，协作证据产生、监管前瞻性和分销规划对于成功的市场渗透和长期的产品永续性仍然至关重要。

製药公司、设备创新者参与企业如何透过产品服务捆绑、策略联盟和证据主导的差异化竞争

气喘药物领域的竞争态势体现了现有製药公司、专业设备创新者、受託製造製造商以及新兴数位医疗参与企业的混合竞争。关键的商业策略强调透过产品服务组合实现差异化，将可靠的药理学与设备的易用性、依从性支持和真实世界证据生成相结合。投资长期病人参与解决方案和医护人员教育的公司正在为替代药物设置清晰的障碍，尤其是在维持治疗领域，因为依从性和技术决定了临床结果。

战略伙伴关係和联盟已成为加速连网型设备、云端分析和专业製造等领域能力建构的常用机制。授权协议和联合开发安排使成熟的药物开发商能够结合硬体和软体专业知识，同时又不影响产品上市速度。同时，契约製造製造商和区域生产基地透过提供灵活的生产能力和合规的组装服务，加快产品上市时间并提升供应链的稳健性，其战略重要性日益凸显。

产品平臺多元化也是一个显着趋势，各公司都在寻求改进医疗设备、联合治疗和强化患者支持计划，以此作为传统研发的补充。同时，竞争差异化越来越依赖透过上市后监测证​​明依从性、降低病情恶化率和成本效益高的治疗途径方面取得的可衡量的改善。能够向付款人和医疗系统提供一致的临床和经济性陈述的公司，将最有可能确保药物在处方集中的投放和长期使用。

为商业、製造和临床领导者提供可行的策略步骤，以增强韧性、改善患者治疗效果并推动与付款人一致的价值提案

产业领导者应优先考虑一系列切实可行的行动，将临床价值与营运韧性和商业性敏捷性结合。首先，考虑将关键设备零件的製造业务外包，以多元化供应商基础，并降低关税相关成本上涨和全球物流中断带来的风险。此步骤应辅以情境规划和灵活的合约模式，以便在必要时快速替换供应商。

第二，投资连网型设备功能和病人参与平台，实际提高依从性并获得真实世界疗效。此类投资将加强付款方对话，并为基于疗效的合约创造机会。第三，将证据产生项目扩展到传统的随机试验之外，纳入真实世界临床试验、註册库以及反映付款者和提供者标准的健康经济学分析。这些数据资产在与大型综合交付网路和国家卫生系统进行合作谈判时至关重要。

第四，调整你的市场进入策略，以反映你的通路的实际状况和最终用户的需求。相应地，为医院药剂师、零售团队和居家照护提供者量身定制支援材料和培训计划。第五，选择性地建立策略伙伴关係关係，以加速你的数位化和製造能力，而不是试图在内部建立所有能力。最后，儘早与监管机构和付款人沟通，使你的临床开发计画与报销要求保持一致，从而降低产品上市后长期面临市场接受障碍的风险。这些综合行动可以为将竞争考察转化为永续竞争优势提供切实可行的蓝图。

结合相关人员访谈、监管机构调查、证据综合和情境分析的严格混合方法研究途径确保了可靠且可操作的见解

本报告所依据的研究结合了多种定性和定量方法，以确保可靠的三段论见解。主要研究包括与各类相关人员进行结构化访谈：执业肺科医生、呼吸治疗师、医院采购负责人、药房主任、付款人以及製造商和设备公司的高级商务领导。此外，我们还与临床医生和付款人举行了咨询圆桌会议，以检验实践模式和报销优先顺序的解释。

二次研究包括对官方监管指南、临床实践指南、产品标籤和同行评审文献的系统性回顾，以建立全面的依证。产业期刊、监管备案文件和企业资料有助于了解竞争格局和产品线动态。数据合成遵循三角测量框架，将主要见解与文献证据交叉引用，以识别趋同主题并减少偏差。

分析方法包括对访谈记录进行定性主题编码、情境分析（用于检验备选假设下供应链和资费的影响）以及付款人路径图谱绘製（用于捕捉区域报销的细微差别）。在适用的情况下，我们也进行了敏感度分析，以评估设备采用和证据产生对处方药目录投放的行为影响。我们也进行了品质保证，以确保调查结果的一致性和可追溯性，包括对调查方法和调查记录进行独立审查。

结论性综合表明，设备创新、现实世界证据和有弹性的供应链对于气喘药物的永续成功至关重要

总而言之，气喘药物领域正处于曲折点，设备发展、新兴证据、监管环境的细微变化以及供应链策略将共同决定商业性可行性和患者影响。透过采用连网型设备技术、投资上市后证据并强化供应链，整合这些因素的机构将能够更好地满足临床医生和付款人的期望，同时提高患者的依从性和疗效。

此外，政策和经济环境，包括关税主导的成本压力和区域准入动态，凸显了敏捷性和前瞻性营运选择的重要性。透过调整产品设计以适应分销现实和临床实践模式，公司可以製定引人注目的价值提案，引起医院、居家医疗机构和药房等相关人员的共鸣。积极主动地建立策略伙伴关係关係，满足付款人证据要求，并严格执行，可以将洞察转化为对患者和医疗保健系统永续的价值。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 扩大双支气管扩张剂吸入器在中度至重度气喘治疗的应用
  • 数位吸入器感测器的成长实现了即时药物依从性追踪和数据分析
  • 针对新型白细胞介素路径治疗气喘的生物单株抗体研发管线不断扩大
  • 越来越多的患者喜欢每日一次的固定剂量复合式吸入器，而不是多剂量方案
  • COVID-19 疫情对远端医疗气喘护理和远端患者监护的影响
  • 非专利吸入皮质类固醇的监管核准正在推动现有市场的价格竞争

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章气喘药物市场（依产品类型）

  • 吸入器
  • 喷雾器
  • 药片和药丸

第九章气喘药物市场（依药物类别）

  • 沙丁胺醇
  • β-促效剂
  • 支气管扩张剂
  • 皮质类固醇
  • 白三烯调节剂

第十章气喘药物市场按交付方式

  • 吸入
  • 口服

第 11 章气喘药物市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第 12 章气喘药物市场（依最终使用者）

  • 门诊手术中心
  • 居家照护环境
  • 医院和诊所

第十三章气喘药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章气喘药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。各国气喘药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • ALK-Abello A/S
    • Amphastar Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • CHIESI Farmaceutici SpA
    • Cipla Limited
    • Dr.Reddy's Laboratories Ltd
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline PLC
    • Hetero Labs Limited
    • Lallemand Inc.
    • Merck KGaA
    • Mundipharma International Limited
    • NIOX Group PLC
    • Novartis AG
    • Novo Holdings
    • OPKO Health, Inc.
    • Pfizer Inc.
    • Sanner GmbH
    • Sanofi SA
    • Sunovion Pharmaceuticals Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Verona Pharma PLC
    • Viatris, Inc.
Product Code: MRR-434CCDA05226

The Asthma Drugs Market is projected to grow by USD 39.62 billion at a CAGR of 6.29% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 24.30 billion
Estimated Year [2025] USD 25.75 billion
Forecast Year [2032] USD 39.62 billion
CAGR (%) 6.29%

An authoritative orientation to the current therapeutic environment, device innovation, regulatory pressures, and stakeholder expectations that define asthma drug strategies

Asthma remains a chronic respiratory condition with persistent clinical and operational challenges that continue to drive innovation across pharmaceutical and device sectors. Treatment paradigms have historically centered on symptom relief and exacerbation prevention, but a steady shift toward precision therapeutics, improved device engineering, and integrated care models is reshaping clinical pathways and procurement priorities. Against this backdrop, stakeholders from manufacturers to providers and payers are reassessing product portfolios, patient support services, and distribution strategies to respond to changing patient expectations, regulatory requirements, and technological possibilities.

The contemporary landscape reflects an intersection of clinical science and systems thinking. Advances in inhaler design and connectivity are enabling adherence monitoring and remote management, while evolving clinical guidance encourages earlier intervention and stratified therapy selection. Concurrently, supply chain considerations, manufacturing specialization, and cost containment pressures are prompting reassessments of sourcing and production footprints. Taken together, these dynamics have created both disruption and opportunity for organizations that can combine clinical credibility with operational agility and data-driven decision making.

How device-digital convergence, personalized treatment pathways, evolving reimbursement priorities, and supply chain resilience are reshaping competitive advantage in asthma therapeutics

The asthma therapeutics environment is experiencing transformative inflection driven by several converging forces that are redefining competitive advantage and patient outcomes. First, device innovation has moved beyond simple delivery mechanics toward integrated digital ecosystems that pair inhalers and nebulizers with sensors, mobile applications, and cloud analytics. This trend enhances medication adherence tracking and enables provider-led interventions between visits, thereby shifting value propositions toward outcomes and engagement rather than product-only offerings.

Second, clinical personalization is gaining momentum as clinicians and payers prioritize phenotype- and biomarker-driven approaches for moderate to severe disease management. Consequently, treatment pathways are becoming more nuanced, favoring targeted agents and combination strategies for patients with distinct inflammatory profiles. Third, regulatory and reimbursement landscapes are evolving to reward real-world effectiveness and cost containment, which increases the importance of robust post-market evidence generation and payer engagement. Moreover, supply chain resilience and procurement agility have grown in importance following global disruptions, prompting manufacturers to reassess sourcing, inventory strategies, and local manufacturing options.

Finally, patient expectations and care delivery models are shifting in parallel. Telehealth adoption, decentralized care, and home-based monitoring have expanded the touchpoints for asthma management and require integrated solutions that simplify use and improve adherence. In sum, these transformative shifts favor organizations that can integrate device innovation, clinical evidence, supply chain adaptability, and stakeholder-aligned value propositions into coherent commercial strategies.

An analytical review of how the United States tariff measures enacted in 2025 have influenced sourcing costs, manufacturing footprints, and procurement strategies across asthma therapeutics

The policy decision to implement new tariffs in the United States in 2025 has had multifaceted implications for the asthma therapeutics supply chain, commercial strategies, and long-term investment choices. Import duties on select raw materials, finished devices, and components increased landed costs for certain manufacturers that rely on globalized sourcing. As a result, procurement teams and contract manufacturers accelerated efforts to re-evaluate supplier contracts, identify nearshore and domestic alternatives, and negotiate longer-term supply agreements to mitigate cost volatility.

Consequently, manufacturers with vertically integrated manufacturing or diversified supplier bases found greater stability, while those with concentrated exposure to affected import categories faced operational pressure. In response, several organizations prioritized reprioritization of capital spend toward local production lines for devices and assembly operations, even as they continued to balance unit economics against regulatory and quality compliance costs. Moreover, tariff-driven cost pressures have influenced pricing discussions with distributors and payers, encouraging stakeholders to emphasize value-added services such as adherence programs and patient support to sustain commercial positioning.

From a strategic standpoint, the tariff environment amplified the importance of agility in sourcing and product design. Firms that proactively redesigned components to use alternative materials or modular architectures saw improved resilience. Additionally, transitional measures-such as re-classifying components, leveraging free trade agreements where applicable, and increasing inventory buffers-helped some organizations absorb short-term shocks. Looking forward, the cumulative impact of these policy changes is prompting long-term reconsideration of supply chain footprint strategies, manufacturing investments, and the balance between cost optimization and continuity of care for patients reliant on inhalers, nebulizers, and oral therapies.

Integrated segmentation analysis revealing how product types, drug classes, delivery modes, distribution channels, and end-user contexts shape clinical adoption and commercial strategies

Segmentation insights reveal distinct commercial and clinical dynamics when examined through product type, drug class, delivery mode, distribution channel, and end-user lenses. When framed by product type, inhalers, nebulizers, and tablets and pills demonstrate divergent adoption drivers: inhalers and nebulizers prioritize device ergonomics, dosing accuracy, and adherence facilitation, while oral formulations emphasize systemic tolerability and convenience for particular patient cohorts. As a result, product development teams must align R&D investments with device usability and patient preference data to maximize clinical uptake.

Viewing the landscape by drug class highlights unique therapeutic and regulatory considerations. Albuterol and beta agonists primarily address acute symptom relief and immediate bronchodilation needs, whereas bronchodilators and corticosteroids form the backbone of maintenance regimens that require longitudinal adherence and safety monitoring. Leukotriene modifiers offer alternative or adjunctive pathways for specific inflammatory phenotypes and can be positioned as oral options for patients who prefer or require noninhaled therapy. Therefore, formulary positioning and clinical messaging must differentiate acute rescue therapies from maintenance approaches while accounting for safety profiles and route-specific advantages.

Delivery mode-classified broadly as inhalable or oral-shapes both clinical outcomes and patient acceptance. Inhalable therapies offer targeted pulmonary deposition and rapid onset, but they demand patient technique competency and sometimes a higher degree of training and follow-up. Oral therapies provide convenience and familiar dosing formats but may present different systemic exposure profiles and adherence challenges. Consequently, commercialization strategies should integrate patient education initiatives and device training programs for inhalable products while reinforcing adherence supports for oral regimens.

Distribution channel considerations further inform go-to-market approaches, with hospital pharmacies, online pharmacies, and retail pharmacies each serving distinct buyer behaviors and logistical constraints. Hospital pharmacies often handle acute and high-acuity cases with institutional purchasing frameworks, online pharmacies provide convenience and subscription models that support chronic therapy continuity, and retail pharmacies remain critical for point-of-care counseling and immediate access. Aligning distribution strategies with anticipated prescribing patterns and payer pathways is therefore essential for maintaining product availability and patient adherence.

Finally, end-user segmentation across ambulatory surgery centers, home care settings, and hospitals and clinics underscores varied utilization contexts and support requirements. Ambulatory surgery centers may prioritize short-acting agents for peri-procedural management, home care settings demand durable and easy-to-use devices with remote monitoring capabilities, and hospitals and clinics require high-reliability supply and comprehensive clinical support materials. Integrating these segmentation layers supports a nuanced commercial playbook that balances product design, evidence generation, and service delivery to meet the expectations of clinicians, caregivers, and patients.

A regionally differentiated perspective on regulatory complexity, payer expectations, and commercial execution across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics influence regulatory pathways, reimbursement frameworks, and commercial priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific, creating distinct opportunities and constraints for asthma therapeutics stakeholders. In the Americas, payer scrutiny and procurement sophistication drive an emphasis on real-world outcomes, cost-effectiveness evidence, and service models that demonstrably reduce exacerbations and hospital admissions. Manufacturers operating in this region are prioritizing comprehensive health economic dossiers and integrated patient support to satisfy formulary decision-makers and large integrated delivery networks.

Across Europe, Middle East & Africa, heterogeneous regulatory regimes and reimbursement environments necessitate adaptive market entry strategies. In some European countries, centralized procurement and value-based contracting play increasing roles, while in parts of the Middle East and Africa, access challenges and infrastructure variability favor robust distribution partnerships and capacity-building programs. Consequently, cross-border strategies must balance centralized evidence generation with locally tailored payer engagement and supply chain solutions.

The Asia-Pacific region presents both rapid adoption potential and complexity due to diverse healthcare systems, regulatory standards, and patient demographics. Many jurisdictions in this region are fast adopters of digital health technologies, providing fertile ground for connected inhaler solutions and remote monitoring integration. At the same time, manufacturers must navigate price sensitivity and local manufacturing expectations, which often require creative commercialization models, technology transfers, and strategic partnerships to support sustainable access and scale. Across all regions, coordinated evidence generation, regulatory foresight, and distribution planning remain central to successful market penetration and long-term product sustainability.

How incumbent pharmaceutical firms, device innovators, and digital entrants are competing through product-service bundles, strategic alliances, and evidence-driven differentiation

Competitive dynamics in the asthma therapeutics arena reflect a blend of established pharmaceutical incumbents, specialized device innovators, contract manufacturing organizations, and emerging digital health entrants. Leading commercial strategies emphasize differentiation through product-service bundles that combine reliable pharmacology with device usability, adherence supports, and real-world evidence generation. Firms that invest in longitudinal patient engagement solutions and provider education create distinct barriers to substitution, particularly for maintenance therapies where adherence and technique determine clinical outcomes.

Strategic partnerships and alliances have become common mechanisms to accelerate capability building in areas such as connected devices, cloud analytics, and specialty manufacturing. Licensing agreements and co-development arrangements allow established drug developers to integrate hardware and software expertise without sacrificing speed to market. At the same time, contract manufacturers and regional production hubs have increased their strategic importance by offering flexible capacity and regulatory-compliant assembly services that reduce time-to-shelf and improve supply chain robustness.

Product pipeline diversification is also a notable trend, with organizations pursuing incremental device improvements, combination therapies, and enhanced patient support programs as complementary levers to traditional R&D. Meanwhile, competitive differentiation increasingly rests on the ability to demonstrate measurable improvements in adherence, reduction in exacerbations, and cost-effective care pathways through robust post-market studies. Firms that can present coherent clinical and economic narratives to payers and health systems will be best positioned to secure formulary placement and long-term utilization.

Actionable strategic steps for commercial, manufacturing, and clinical leaders to build resilience, enhance patient outcomes, and drive payer-aligned value propositions

Industry leaders should prioritize a set of pragmatic actions that align clinical value with operational resilience and commercial agility. First, diversify supplier bases and consider nearshoring manufacturing for critical device components to reduce exposure to tariff-related cost spikes and global logistics disruptions. This step should be complemented by scenario planning and flexible contracting models that allow rapid supplier substitution when necessary.

Second, invest in connected-device capabilities and patient engagement platforms that demonstrably improve adherence and collect real-world outcomes. Such investments can strengthen payer conversations and create opportunities for outcomes-based contracting. Third, expand evidence-generation programs beyond classical randomized trials to include real-world studies, registries, and health economics analyses that reflect payer and provider decision criteria. These data assets will be critical when negotiating placement with large integrated delivery networks and national health systems.

Fourth, calibrate go-to-market strategies to reflect distribution channel realities and end-user needs; tailor support materials and training programs for hospital pharmacists, retail teams, and home-care providers accordingly. Fifth, pursue selective strategic partnerships to accelerate digital and manufacturing capabilities rather than attempting to build all competencies internally. Finally, engage regulators and payers early to align clinical development plans with reimbursement requirements, reducing the risk of protracted uptake barriers following product launch. Together, these actions offer a pragmatic roadmap for converting insights into durable competitive advantage.

A rigorous mixed-methods research approach combining stakeholder interviews, regulatory review, evidence synthesis, and scenario analysis to ensure credible actionable insights

The research underpinning this report combined multiple qualitative and quantitative approaches to ensure robust, triangulated insights. Primary research included structured interviews with a range of stakeholders: practicing pulmonologists, respiratory therapists, hospital procurement officers, pharmacy directors, payers, and senior commercial leaders from manufacturers and device firms. These interviews were complemented by advisory roundtables with clinicians and payers to validate interpretation of practice patterns and reimbursement priorities.

Secondary research encompassed systematic reviews of public regulatory guidance, clinical practice guidelines, product labeling, and peer-reviewed literature to construct a comprehensive evidence baseline. Trade publications, regulatory filings, and corporate disclosures aided understanding of competitive posture and pipeline dynamics. Data synthesis followed a triangulation framework in which primary insights were cross-referenced with documentary evidence to identify convergent themes and reduce bias.

Analytical methods included qualitative thematic coding for interview transcripts, scenario analysis to test supply chain and tariff impacts under alternative assumptions, and payer pathway mapping to capture regional reimbursement nuances. Where applicable, sensitivity analyses were performed to assess the behavioral implications of device adoption and evidence generation on formulary positioning. Throughout, quality assurance measures ensured consistency and traceability of findings, including independent review of methodology and source logs.

A conclusive synthesis underscoring why device innovation, real-world evidence, and resilient supply chains are essential to sustainable success in asthma therapeutics

In conclusion, the asthma therapeutics landscape is at an inflection point where device evolution, evidence generation, regulatory nuance, and supply chain strategy jointly determine commercial viability and patient impact. Organizations that integrate these dimensions-by deploying connected-device technologies, investing in post-market evidence, and fortifying supply chains-will be better equipped to meet clinician and payer expectations while improving adherence and outcomes for patients.

Moreover, the policy and economic environment, including tariff-driven cost pressures and regional access dynamics, underscores the need for agility and forward-looking operational choices. By aligning product design with distribution realities and clinical practice patterns, companies can create defensible value propositions that resonate with stakeholders across hospitals, home care settings, and pharmacies. The path forward favors firms that are proactive in forming strategic partnerships, responsive to payer evidence requirements, and disciplined in execution, thereby translating insight into sustainable value for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expanding use of dual bronchodilator inhalers for moderate to severe asthma management
  • 5.2. Growth of digital inhaler sensors enabling real time adherence tracking and data analytics
  • 5.3. Rising pipeline of biologic monoclonal antibodies targeting novel interleukin pathways in asthma treatment
  • 5.4. Increasing patient preference for once daily fixed dose combination inhalers over multiple dosing regimens
  • 5.5. Impact of COVID 19 pandemic on telehealth driven asthma care and remote patient monitoring adoption
  • 5.6. Regulatory approvals of generic inhaled corticosteroids driving price competition in established markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Asthma Drugs Market, by Product Type

  • 8.1. Inhalers
  • 8.2. Nebulizers
  • 8.3. Tablets & Pills

9. Asthma Drugs Market, by Drug Class

  • 9.1. Albuterol
  • 9.2. Beta Agonists
  • 9.3. Brochodilators
  • 9.4. Corticosteroids
  • 9.5. Leukotriene Modifiers

10. Asthma Drugs Market, by Delivery Mode

  • 10.1. Inhalable
  • 10.2. Oral

11. Asthma Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Asthma Drugs Market, by End Users

  • 12.1. Ambulatory Surgery Centers
  • 12.2. Home Care Settings
  • 12.3. Hospitals & Clinics

13. Asthma Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Asthma Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Asthma Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. ALK-Abello A/S
    • 16.3.2. Amphastar Pharmaceuticals, Inc.
    • 16.3.3. AstraZeneca PLC
    • 16.3.4. Bayer AG
    • 16.3.5. Boehringer Ingelheim International GmbH
    • 16.3.6. CHIESI Farmaceutici S.p.A.
    • 16.3.7. Cipla Limited
    • 16.3.8. Dr.Reddy's Laboratories Ltd
    • 16.3.9. F. Hoffmann-La Roche Ltd.
    • 16.3.10. GlaxoSmithKline PLC
    • 16.3.11. Hetero Labs Limited
    • 16.3.12. Lallemand Inc.
    • 16.3.13. Merck KGaA
    • 16.3.14. Mundipharma International Limited
    • 16.3.15. NIOX Group PLC
    • 16.3.16. Novartis AG
    • 16.3.17. Novo Holdings
    • 16.3.18. OPKO Health, Inc.
    • 16.3.19. Pfizer Inc.
    • 16.3.20. Sanner GmbH
    • 16.3.21. Sanofi S.A.
    • 16.3.22. Sunovion Pharmaceuticals Inc.
    • 16.3.23. Teva Pharmaceutical Industries Ltd.
    • 16.3.24. Verona Pharma PLC
    • 16.3.25. Viatris, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ASTHMA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ASTHMA DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ASTHMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ASTHMA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ASTHMA DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ASTHMA DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ASTHMA DRUGS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ASTHMA DRUGS MARKET SIZE, BY TABLETS & PILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ALBUTEROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ASTHMA DRUGS MARKET SIZE, BY BROCHODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ASTHMA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ASTHMA DRUGS MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ASTHMA DRUGS MARKET SIZE, BY INHALABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ASTHMA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ASTHMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ASTHMA DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ASTHMA DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ASTHMA DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 178. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 185. AFRICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. AFRICA ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. AFRICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. AFRICA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. AFRICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 190. AFRICA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ASTHMA DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. ASEAN ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. ASEAN ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. ASEAN ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. ASEAN ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. ASEAN ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 216. ASEAN ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 223. GCC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GCC ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GCC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. GCC ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. GCC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 228. GCC ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 229. GCC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 230. GCC ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 231. GCC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. GCC ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. GCC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 234. GCC ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 247. BRICS ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. BRICS ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. BRICS ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. BRICS ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. BRICS ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. BRICS ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 253. BRICS ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 254. BRICS ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 255. BRICS ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. BRICS ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. BRICS ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 258. BRICS ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 259. G7 ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. G7 ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. G7 ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. G7 ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. G7 ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. G7 ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. G7 ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 266. G7 ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 267. G7 ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. G7 ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. G7 ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 270. G7 ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 271. NATO ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NATO ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NATO ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. NATO ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. NATO ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 276. NATO ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 277. NATO ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 278. NATO ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 279. NATO ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. NATO ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. NATO ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 282. NATO ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL ASTHMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 289. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 295. CANADA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. CANADA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. CANADA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. CANADA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 299. CANADA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 300. CANADA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 301. CANADA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. CANADA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. CANADA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 304. CANADA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 305. MEXICO ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. MEXICO ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. MEXICO ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. MEXICO ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. MEXICO ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 310. MEXICO ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 311. MEXICO ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. MEXICO ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. MEXICO ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 314. MEXICO ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 315. BRAZIL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. BRAZIL ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 320. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 321. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. BRAZIL ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 323. BRAZIL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 324. BRAZIL ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED KINGDOM ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 335. GERMANY ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. GERMANY ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. GERMANY ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 338. GERMANY ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 339. GERMANY ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 340. GERMANY ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 341. GERMANY ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 342. GERMANY ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 343. GERMANY ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 344. GERMANY ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 345. FRANCE ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. FRANCE ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. FRANCE ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 348. FRANCE ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 349. FRANCE ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 350. FRANCE ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 351. FRANCE ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 352. FRANCE ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 353. FRANCE ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 354. FRANCE ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 355. RUSSIA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 356. RUSSIA ASTHMA DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 357. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 358. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 359. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 360. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 361. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 362. RUSSIA ASTHMA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 363. RUSSIA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 364. RUSSIA ASTHMA DRUGS MARKET SIZE, BY END USERS, 2025-2032 (US